Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy

Panwen Tian,Hao Zeng,Liyan Ji,Zhenyu Ding,Li Ren,Wen Gao,Zaiwen Fan,Lin Li,Xiuning Le,Pansong Li,Min Zhang,Xuefeng Xia,Jianjun Zhang,Yalun Li,Weimin Li

Lung Cancer（2021）

引用 10|浏览11

暂无评分

摘要

•ERBB2-ex20ins in lung adenocarcinoma (LUAD) exhibited low TMB and negative PD-L1.•30.8% of 13 ERBB2-ex20ins mutant-LUAD patients responded to chemoimmunotherapy.•Targeted-sequencing aid to identify patients who would benefit from chemoimmunotherapy.

查看译文

关键词

Lung adenocarcinoma,ERBB2 exon 20 insertion,Chemoimmunotherapy,Efficacy,Response,Prognosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要